Humanized anti-HLA-DR antibodies
The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.
Immunomedics, Inc.
C C C C A C C C C C C A A A A A A A C A A A A C A C A A C C A A
C07K C07K C07K C07K A61K C07K C07K C07K C07K C07K C07K A61K A61K A61P A61P A61K A61P A61K C07K A61K A61K A61P A61P C07K A61K C07K A61P A61K C07K C07K A61P A61P
additional additional additional inventional inventional inventional inventional additional additional additional additional additional inventional inventional inventional inventional inventional additional additional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional additional inventional inventional
David M. Chien-Hsing Hans J.
Goldenberg Chang Hansen